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Boston, Massachusetts
Recent advances in genetics and proteonomics have great
potential to help tailor treatment to individual patients in
remarkable ways. A focus of intense research is on “clopi-
dogrel nonresponders,” who despite treatment with
conventional-dose clopidogrel still demonstrate high on-
treatment platelet reactivity (HTPR), which has been asso-
ciated with in-stent thrombosis and recurrent cardiovascular
events (1). This decreased response to clopidogrel is thought
to affect roughly one-third of patients (2). Several genetic
polymorphisms have been linked to reduced hepatic metab-
olism of clopidogrel (the most prevalent of which is
CYP2C19), leading to a lower concentration of the active
metabolite (3). This pathophysiological explanation lends
itself to clinical applications, because targeting those pa-
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tients with a positive genetic screen or HTPR after drug-
eluting stents (DES) with a more effective antiplatelet agent
may prove an effective strategy. Recent trials have shown
both prasugrel (TRITON–TIMI 38 [Trial to Assess Im-
provement in Therapeutic Outcomes by Optimizing Plate-
let Inhibition with Prasugrel–Thrombolysis In Myocardial
Infarction 38]) and ticagelor (PLATO [PLATelet inhibi-
tion and patient Outcomes]) yield benefits over clopidogrel in
patients with acute coronary syndromes, and more effectively
suppress platelet reactivity (PRINCIPLE–TIMI 44 [Prasugrel in
Comparison to Clopidogrel for Inhibition of Platelet Activa-
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44 trial], PLATO Platelet), setting the stage for their use as
alternatives to clopidogrel.
The 2011 update to the American College of Cardiology/
American Heart Association guidelines for the management
of unstable angina/non–ST-segment elevation myocardial
infarction reflects the growing consensus that genetic and
platelet function testing are useful in selected patients,
mainly those at a increased risk of future events (4).
Currently, platelet function testing carries a Class IIb
recommendation, Level of Evidence: B, but has yet to be
widely implemented. Among the reasons for this: 1) there
are many platelet function assays available, but there is no
clear consensus as to which is the best; 2) setting a cutoff
value to define HTPR is challenging; and 3) as of yet, there
are limited data that alteration of therapy based on HTPR
improves outcomes (3). To address these issues, a compar-
ison of platelet function assays suggests that the VerifyNow
P2Y12 assay (Accumetrics, San Diego, California) may be
the most practical test currently available, as it is inexpen-
sive, easy to use, and yields comparable results to the
standard light transmittance aggregometry (5). A cutoff of
235 to 240 P2Y12 reaction units (PRU) to define HTPR
as measured by VerifyNow was recently endorsed by the
American College of Cardiology (3). Moreover, modifying
treatment based on the presence of HTPR defined by
VerifyNow is the focus of ongoing clinical trials, and
GRAVITAS (Gauging Responsiveness With A Veri-
fyNow Assay-Impact on Thrombosis And Safety) was
the first large-scale trial to study this, although no benefit
was seen of doubling of the clopidogrel dose in patients
with HTPR (6).
In the paper by Park et al. (7) in this issue of the Journal,
the VerifyNow P2Y12 assay failed to demonstrate a signif-
icant difference in event rates: the occurrence of the primary
endpoint was essentially unchanged in those with HTPR
and those without (2.8% vs. 2.4% at 2 years; p  0.18), and
the addition of HTPR as a risk factor to a multivariate
regression analysis did not improve prognosis of future
cardiac events. One strength of this study was that patients
were followed a median of 2.2 years, longer than other
comparable studies; but a weakness was the low event rate,
thus limiting the power of the study. This may in part be
explained by the absence of periprocedural myocardial
infarction in the primary endpoint, as has been used in
recent observational trials with higher event rates (5).
Of interest, in the current study, the prevalence of HTPR
was much higher at 58.3%, in contrast to GRAVITAS and
prior studies, where the prevalence of HTPR was 40.7%.
The reasons for this degree of HTPR are unclear, perhaps
due to increased genetic polymorphisms for CYP2C19 in
the Korean patient population. Thus, integrating the cur-
rent study with GRAVITAS and many prior studies,
platelet function (perhaps combined with genetic) testing
continues to hold promise as a tool to tailor therapy, but the
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In a second aim of the current study, the authors show
that individuals with C-reactive protein (CRP) 3.0 mg/l
are at higher risk for cardiovascular events following DES
(5.6% vs. 1.7% at 2 years, p  0.001). The addition of CRP
to standard risk factors improved the ability to prognosticate
patient outcomes modestly (increase of the C-statistic from
0.729 to 0.759, p  0.03). These results are consistent with
a recent meta-analysis that shows CRP concentration has
continuous associations with the risk of CAD, ischemic
stroke, and vascular mortality (8). Targeting patients with
CRP 2 mg/l for primary prevention with statins appears
to lead to improved outcomes in patients at intermediate
risk (9). In the setting of acute coronary syndromes, elevated
CRP was independently correlated with increased 14-day
mortality in TIMI 11A. Additionally, in PROVE IT–
TIMI 22 (Pravastatin or Atorvastatin Evaluation and In-
fection Therapy–Thrombolysis In Myocardial Infarction
22), patients with elevated CRP post-treatment also had
increased risk of cardiovascular events. The current study is
consistent with prior studies linking CRP to stent throm-
bosis and cardiovascular events (10), and is supportive of the
growing body of evidence suggestive that CRP can be used
to indentify high-risk patients who in turn can be targeted
for intensive primary and secondary prevention.
Importantly, this study identifies those patients with
elevated CRP as a high-risk group following DES, and
suggests that patients with both elevated CRP and HTPR
are at even higher risk. This raises the question of whether
patients with high CRP would benefit the most from
platelet function testing and tailored antiplatelet therapy. As
CRP is a marker of inflammation, it is plausible that
patients with elevated CRP would have higher platelet
reactivity at baseline, be more likely to exhibit HTPR, and
benefit from more potent antiplatelet agents. Additionally,
given the results of this current study, it may be worthwhile
to investigate whether treating patients with elevated CRP
following DES with intensive statin therapy may be an
effective means of secondary prevention, regardless of low-
density lipoprotein level.
Integrating the current evidence and practice guidelines,
genetic and platelet function testing are suggested in selected
atients that would benefit the most from testing. This patient
roup is still being defined, but might include patients with
rior stent thrombosis, obese or very low body weight individ-
als, and (incorporating the current study’s results) patients
ith CRP 3 mg/l. As this area of research matures, thecomparative utility of genetic versus platelet function testing
should be investigated prospectively, and the definition of
HTPR further refined. Several ongoing trials seek to
elucidate whether treatment strategies of higher dose
clopidogrel (NCT01235351 and NCT00827411) and
prasugrel (NCT01090336) (or ticagrelor) actually im-
prove outcomes. Personalizing medical therapy to target
HTPR and CRP may thus be on the horizon. With the
proper focus, this may lead to improved patient outcomes
following DES in the near future.
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